Related Experiment Video
Updated: May 16, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Hormone replacement therapy after endometrial cancer
K Manley1, K Edey, J Braybrooke
1Department of Gynaecology, St Michaels Hospital, Bristol BS2 8EG, UK.
Menopause International
|November 14, 2012
Summary
This review examines hormone replacement therapy (HRT) safety for women with surgically induced menopause due to endometrial cancer. It discusses estrogen, combined HRT, topical treatments, and testosterone for symptom management.
Area of Science:
- Gynecological Oncology
- Reproductive Endocrinology
- Oncology Nursing
Background:
- Endometrial cancer is the most common gynecological malignancy in the UK.
- Surgically induced menopause significantly impacts quality of life and symptom control in these patients.
- Hormone replacement therapy (HRT) use in this population remains a subject of clinical debate.
Purpose of the Study:
- To review the current evidence on the safety of estrogen-only and combined HRT in women with surgically induced menopause.
- To outline alternative and topical therapies for symptom management.
- To discuss the emerging data on testosterone use for symptom control.
Main Methods:
- Literature review of existing studies and clinical data.
- Analysis of safety profiles for different HRT formulations.
- Evaluation of evidence for non-hormonal and complementary therapies.
Main Results:
- Evidence regarding the safety of estrogen-only and combined HRT is presented and discussed.
- The efficacy and safety of topical vaginal therapies are outlined.
- Current data on testosterone for managing menopausal symptoms in this cohort are summarized.
Conclusions:
- The review provides a comprehensive overview of HRT safety and alternative treatments for women experiencing surgically induced menopause post-endometrial cancer treatment.
- Informed decision-making regarding symptom management and quality of life can be supported by this evidence-based summary.
Related Concept Videos
01:28Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
01:24Disorders of the Female Reproductive System
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
01:30Hormonal Control of the Ovarian Cycle
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Ovarian Cycle
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...